



Used in Lieu of PTO/SB/05A/B
(Based on PTO 10-07 version)

Substitute for form 1449/PTO			Complete If Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Application Number	10/045,842-Conf# 2394	
			Filing Date	October 26, 2001	
			First Named Inventor	Lin	
			Art Unit	1762	
			Examiner Name	E.C. Cameron	
Sheet	1	of	2	Attorney Docket Number	80929(303655)

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Codes* (if known)				
	AA*	US-4,714,621		11-06-1986		
	AB*	US-3,072,122		11-08-1963		
	AC*	US-3,678,150		07-18-1972		
	AD*	US-3,123,212		03-03-1964		
	AE*	US-2,619,962		12-02-1952		
	AF*	US-2,893,392		07-07-1959		
	AG*	US-3,221,739		12-07-1965		
	AH*	US-3,221,740		12-07-1965		

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	† ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		MM-DD-YYYY			
	BA	WO-02/07813		01-31-2002			✓
	BB	WO-96/10630		04-11-1996			✓
	BC	GB-878,788		10-04-1961			✓
	BD	EP-1 358 896		11-05-2003			✓
	BE	WO-00/35530		06-22-2000			✓
	BF	WO-02/074173		09-26-2002			✓
	BG	WO-00/44438		08-03-2000			✓
	BH	WO-00/12173		03-09-2000			✓
	BI	WO-96/03978		02-15-1996			✓
	BJ	WO-97/48440		12-24-1997			✓
	BK	WO-99/64580		12-16-1999			✓
	BL	WO-98/28037		07-02-1998			✓
	BM	GB-0017939.4					✓
	BN	EP-1 517 722		08-16-2006			✓
	BO	EP-1 301 238		09-22-2004			✓

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	BOS2 670368.1	/Erma Cameron/	Date Considered	06/26/2008
--------------------	---------------	----------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ECC/

Used in Lieu of PTO/SB/05A/B
(Based on PTO 10-07 version)

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/045,842-Conf# 2394
		Filing Date	October 26, 2001
		First Named Inventor	Lin
		Art Unit	1762
		Examiner Name	E.C. Cameron
		Attorney Docket Number	80929(303655)
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Gribbon, et al., "Stabilisation of Vaccines Using Trehalose (Q-24) Technology", Brown F(ed): New Approaches to Stabilisation of Vaccines Potency, Dev Biol Stand. Basel, Karger, 1996, vol 87, pp 193-199.	
	CB	Franks, "Solid aqueous solutions", Pure & Appl. Chem., Vol. 65, No. 12, pp. 2527-2537, 1993.	
	CC	Colaco et al., RESEARCH/Extraordinary Stability of Enzymes Dried in Trehalose: Simplified Molecular Biology", Bio/Technology Vol 10 September 1992, pp. 1007-1011.	
	CD	"Report of the Technical Review Group Meeting", WHO, 7-8 June 1999, pp. 1-88.	
	CE	"A plethora of hi-Tech vaccines-genetic, edible, sugar glass, and more", Children's Vaccine Initiative, CVI Forum 18, 1999, pp. 1-24.	
	CF	"Report on the first meeting of the steering committee on Immunization Safety", WHO Geneva, 25-26 Oct (1999), pp. 1-44.	
	CG	Roberts, et al., "Solute Structure as a Determinant of Ionophoretic Transport", Mechanisms of Transdermal Drug Delivery, R.O. Potts and R. H. Guy (Ed.), Marcel Dekker (1997) 291-349.	
	CH	Chang, et al., "Use of Subambient Thermal Analysis to Optimize Protein Lyophilization", Cryobiology 29, (1992), pp. 632-656.	
	CI	Wang, "Lyophilization and development of solid protein pharmaceuticals", International Journal of Pharmaceutics 203 (2000), pp. 1-60.	
	CJ	Carpenter, et al., "Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice", Pharmaceutical Research Vol. 14, No. 8, 1997, pp. 969-975.	
	CK	Huang, et al., "Microencapsulation for Gene Delivery", Encyclopedia of Controlled Drug Delivery, John Wiley & Sons, Inc. (1999), pp. 546-553.	
	CL	General Policy Issues, "Wider access to HIV drugs now a reality", WHO Drug Information, Vol. 12, No. 2, 1998, pp. 67-99.	
	CM	Roos, "Melting and glass transitions of low molecular weight carbohydrates", Carbohydrate Research, 238, (1993), pp. 39-48.	
	CN	Chunk et al., "Liquid film coating": Scientific principles and their technological implications", Kistler and Schweizer, Editors, Chapin & Hall, London (1997), pp. 673-708.	
	CO	"HIV/PPD Conjugate Vaccine Active in Clinical Trial" (1998).	
	CP	"Glass pharmacy", New Science Publications, March 8, 1997, pp. 24-27.	
	CQ	Fox, "Putting Proteins Under Glass", Science, Vol. 267, March 31 1999, pp. 1922-1923.	
	CR	Henry et al., "Microfabricated Microneedles: A Novel Approach to Transdermal Drug Delivery", Journal of Pharmaceutical Sciences, Vol. 87, No. 8, August 1998, pp.922-925.	
	CS	Roia, Ph.D., "Immunizing Agents and Diagnostic Skin Antigens", Remington's 17 th Edition, Pharmaceutical Sciences (1985), pp. 1380-95, Mack Publishing Company, Pennsylvania.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	BOS2 670368.1 /Erma Cameron/	Date Considered	06/26/2008
-----------------------	------------------------------	--------------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /ECC/